Author

R. De Luca

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 4 Research Focus:drug response / drug discovery· 2 Organism:C. elegans· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:protein structure· 1

Frequent Co-Authors

D. Neri· 4 shared A. Villa· 3 shared B. Gouyou· 2 shared T. Ongaro· 2 shared A. Kerschenmeyer· 1 shared A. Sannino· 1 shared B. Ziffels· 1 shared E. Puca· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBioengineering

D. Neri

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antibody-based delivery of Interleukin-9 to neovascular structures: therapeutic evaluation in cancer and arthritis

B. Gouyou, T. Ongaro, S. Cazzamalli, R. De Luca, A. Kerschenmeyer, P. Valet, A. Villa, D. Neri, M. Matasci

This study evaluates the therapeutic potential of IL9 delivered via antibody-based fusion proteins in cancer and arthritis models, finding modest anti-tumor activity but no benefit in arthritis.

bioRxiv · Aug 26, 2020Bioengineering

The immunocytokine L19-TNF eradicates Sarcomas in combination with Chemotherapy or with immune check-point inhibitors

R. Corbellari, L. Nadal, A. Villa, D. Neri, R. De Luca

The paper shows that combining the immunocytokine L19-TNF with chemotherapy or immune checkpoint inhibitors improves tumor remission in a sarcoma mouse model.

bioRxiv · Feb 4, 2020Cancer Biology

A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas

R. De Luca, B. Gouyou, T. Ongaro, A. Villa, B. Ziffels, A. Sannino, G. Buttinoni, S. Galeazzi, M. Mazzacuva, D. Neri

This paper describes the development and characterization of a dual cytokine-antibody fusion protein targeting carbonic anhydrase IX in renal cell carcinomas, showing tumor localization and growth inhibition.

Frontiers in Oncology · Nov 13, 2019Peer-reviewedBioengineering

Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice

E. Puca, R. De Luca, F. Seehusen, J. M. M. Rodriguez, D. Neri

This study compares bolus and fractionated administration of two antibody-cytokine fusions in mice, finding that fractionation reduces toxicity for one but increases efficacy for another.

bioRxiv · Nov 7, 2019Pharmacology & Toxicology